Minster Pharmaceuticals plc, through its subsidiary, Minster Research Limited, develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions in the United Kingdom. Its products pipeline comprises Tonabersat, which is in Phase IIb clinical trial for the prevention and treatment of migraine; and Sabcomeline, a Phase IIa clinical trial product for the management of cognitive decline and negative symptoms in schizophrenia. The company is based in Saffron Walden, the United Kingdom.

Pharming Group N.V. is a Netherlands-based biotechnology company. The Company has facilities both in the Netherlands and the United States. Pharming develops products for the treatment of diseases with significant medical needs, including genetic disorders, diseases associated with the immune system, ageing diseases, and nutritional products. The Company’s technologies include platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of DNA repair via its subsidiary DNage BV. Pharming products under development are divided into three categories: biopharmaceuticals, biomaterials, and bio-nutritionals. Products in the most advanced stage of development and closest to commercialization are Rhucin and human lactoferrin for use in food products. Pharming has several partnerships and collaborations with, inter alia, AgResearch, US Army, Aslan and Schering-Plough.

Medicis Pharmaceutical Corporation was founded in 1987 and is headquartered in Scottsdale, Arizona. Medicis Pharmaceutical Corporation operates as a specialty pharmaceutical company in the United States and Canada. It develops and markets products for the treatment of dermatological, aesthetic, and podiatric conditions. The company's products address various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis, and cosmesis. Its products include DYNACIN for the treatment of acne and acne-related dermatological conditions; PLEXION, a cleanser product; SOLODYN for the treatment of inflammatory lesions; TRIAZ, a benzoyl peroxide pad for the topical treatment of acne vulgaris; and ZIANA, a gel used on the skin for treatment of acne in patients 12 and older.Medicis Pharmaceutical also offers LOPROX, a shampoo; PERLANE and RESTYLANE for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds; and VANOS, a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. In addition, Medicis Pharmaceutical provides non-dermatological products, including AMMONUL for treating hepatic encephalopathies; and BUPHENYL for the treatment of urea cycle disorder. The company sells its products primarily to wholesale pharmaceutical distributors and retail pharmacy chains. It has a joint development agreement with IMPAX Laboratories, Inc. to develop of five strategic dermatology product opportunities, including an advanced-form SOLODYN product; a strategic alliance with AAIPharma, Inc. for the development, commercialization, and license of a key dermatologic product, SOLODYN; and a strategic collaboration with Hyperion Therapeutics, Inc. for the research and development of a compound referred to as GT4P for the treatment of urea cycle disorder and hepatic encephalopathies.

Norgine Limited was founded in 1906 and is based in Harefield, the United Kingdom with regional offices in Tunisia and Saudi Arabia. It has manufacturing sites in Dreux, France; and Hengoed, the United Kingdom. The company has subsidiaries in the United Kingdom, France, Germany, Belgium, the Netherlands, Denmark, Switzerland, Austria, Italy, and Spain, as well as in Australia, and South Africa. Norgine Limited is a subsidiary of Norgine Europe B.V. Norgine Limited, a specialty pharmaceutical company, develops, manufactures, and markets products in the areas of gastroenterology, hepatology, and pain management in Europe. It offers products for the treatment of chronic constipation and faecal impaction, bowel preparation prior to colonoscopy, ulcerative colitis, Crohn's disease, duodenal and benign gastric ulcers, traveler’s diarrhoea, and pain, as well as provides antitussive medications and products for the relief of smooth muscle spasm. The company also provides assistance in the development and launch of pharmaceutical products for companies.

Coating Place, Inc. is a privately owned contract manufacturing organization specializing in pharmaceutical grade Wurster fluid bed coating services for encapsulation/microencapsulation of solid particulate materials such as powders, granules, crystals, and capsules. Services offered include pharmaceutical GMP contract manufacturing, process validation, technology transfer, scale-up, formulation development, feasibility studies, and GMP analytical laboratory support.Applications include controlled oral delivery such as enteric, delayed, or sustained release, taste, odor masking, and moisture or oxygen barrier application for Rx prescription, OTC, and controlled substance markets. Facilities are permitted for solvent applications; thus, allowing solvent, aqueous, and hot melt Wurster processing.

VIVUS, Inc. company was founded in 1991 and is headquartered in Mountain View, California. VIVUS, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company’s product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in Phase III clinical trials for obesity and in Phase II clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which the two of the Phase III studies are in process and one Phase III study has been completed; Qnexa for treating diabetes, for which a one-year Phase II study has been completed; Avanafil, is being developed for the treatment of erectile dysfunction; for which Phase III studies are in process, and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a Phase II study has been completed.

ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania. ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Its products include Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains; and Cinryze for the prevention of hereditary angioedema attacks. The company's products in development include Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus disease; and non-toxigenic strains of C. difficile, which is in preclinical stage for the treatment and prevention of CDI. It licensed the third product development candidate, an intranasal formulation of pleconaril, to Schering-Plough for the treatment of picornavirus infections in the U.S. and Canada. It sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. The company has strategic relationships with Eli Lilly and Company, GlaxoSmithKline, Schering-Plough Corporation, and Sanofi-Aventis.

Vaxon Biotech is a biopharmaceutical company focused on the treatment of cancers and related malignancies. Disease targets include breast, lung, pancreatic, and prostate cancer. The company's claim to fame is its development of optimized cryptic peptide antigens (substances that trigger protein responses in the immune system), which have shown early progress in the immune response against these cancers. The company's development products are classified as therapeutic vaccines and are developed to trigger the immune system to attack malignant cells in solid tumors while steering clear from normal cells.

Bioheart, Inc. company was founded in 1999 and is headquartered in Sunrise, Florida. Bioheart, Inc. is a biotechnology company focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic acute heart damage and peripheral vascular disease. MyoCell is a clinical therapy designed to populate regions of scar tissue within a patient’s heart with living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company’s clinical trials of MyoCell include the SEISMIC Trial, a completed 40 patient Phase II clinical trial conducted in Europe, and the MYOHEART Trial, a completed 20 patient, Phase I dose escalation trial conducted in the United States. In its pipeline, the Company has multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilizing autologous cells genetically modified to express additional growth proteins.

Formatech provides contract development services for pharmaceutical companies, including cell culture and fermentation, pre-formulation, dosage form, and purification development services. Its dosage forms include liquid, controlled release, tablets, capsules as well as topicals, such as gels, ointments, and creams. It also provides project management services to its contract development customers. The company also offers manufacturing services, such as aseptic fill, finishing, and lyophilization. Formatech's specializations include small molecules, vaccines, and monoclonal antibodies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.